IRIS
RASI, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.520
EU - Europa 2.346
AS - Asia 1.259
SA - Sud America 14
Continente sconosciuto - Info sul continente non disponibili 10
AF - Africa 4
OC - Oceania 4
Totale 29.157
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.487
SG - Singapore 577
CN - Cina 492
UA - Ucraina 412
DE - Germania 342
IT - Italia 331
IE - Irlanda 281
PL - Polonia 258
FR - Francia 209
RU - Federazione Russa 163
SE - Svezia 113
KR - Corea 112
GB - Regno Unito 107
FI - Finlandia 84
CA - Canada 30
JP - Giappone 22
IN - India 14
BR - Brasile 10
BE - Belgio 9
HK - Hong Kong 9
NL - Olanda 9
UZ - Uzbekistan 9
EU - Europa 8
IL - Israele 7
AT - Austria 6
CZ - Repubblica Ceca 6
AU - Australia 4
ES - Italia 4
VN - Vietnam 4
CL - Cile 3
IR - Iran 3
RO - Romania 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
GR - Grecia 2
NG - Nigeria 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
TR - Turchia 2
CH - Svizzera 1
CR - Costa Rica 1
DM - Dominica 1
EC - Ecuador 1
EG - Egitto 1
GH - Ghana 1
HU - Ungheria 1
ID - Indonesia 1
LK - Sri Lanka 1
LT - Lituania 1
LV - Lettonia 1
MX - Messico 1
MY - Malesia 1
SI - Slovenia 1
Totale 29.157
Salva come PNG Salva come JPEG
Città #
Woodbridge 7.673
Wilmington 7.198
Houston 6.002
Ann Arbor 762
Fairfield 638
Singapore 491
Jacksonville 384
Chandler 354
Ashburn 323
Dublin 279
Kraków 257
Seattle 241
Cambridge 227
Medford 227
Beijing 203
Dearborn 155
Santa Clara 108
Lawrence 100
Rome 92
Hangzhou 78
Zhengzhou 76
Mülheim 64
New York 49
San Diego 46
Milan 35
Moscow 27
Menlo Park 25
Toronto 23
Boardman 21
Shanghai 21
Falls Church 19
Hefei 19
University Park 18
London 17
Nanjing 16
Verona 16
San Mateo 15
Norwalk 14
Redwood City 13
Yongsan-gu 13
Mountain View 11
Kunming 10
Fukuoka 9
Brussels 8
Bologna 7
Los Angeles 7
Munich 7
Nürnberg 7
Palo Alto 7
Saint Petersburg 7
Brno 6
Chengdu 6
Detroit 6
Nuremberg 6
Seoul 6
Guangzhou 5
Helsinki 5
Nanchang 5
Redmond 5
Ridgeland 5
Vienna 5
Council Bluffs 4
Hanoi 4
Jinan 4
Kilburn 4
Leawood 4
Naples 4
Shenyang 4
Washington 4
Ahmedabad 3
Alghero 3
Auburn Hills 3
Baotou 3
Changsha 3
Chiswick 3
Chongqing 3
Forlì 3
Hyderabad 3
Indiana 3
Ottawa 3
San Francisco 3
São Paulo 3
Tai Po Kau 3
Yangcheon-gu 3
Ypsilanti 3
Abuja 2
Acton 2
Aliminusa 2
Amsterdam 2
Augusta 2
Berlin 2
Camerino 2
Halifax 2
Incheon 2
Lappeenranta 2
Lastra a Signa 2
Madrid 2
Mapo-gu 2
Minturno 2
Ningbo 2
Totale 26.589
Salva come PNG Salva come JPEG
Nome #
Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance 500
Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats 491
Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1. 461
Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer 450
ANTITUMOR EFFECT OF COMBINED TREATMENT WITH THYMOSIN ALPHA-1 AND INTERLEUKIN-2 AFTER 5-FLUOROURACIL IN LIVER METASTASES FROM COLORECTAL-CANCER IN RATS 443
Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: evidence for an Akt-mediated cross-talk between NHE-1 activity and Wnt/β-catenin signaling 443
Combination low-dose lymphoblastoid interferon and thymosin alpha(1) therapy in the treatment of chronic hepatitis B 439
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma 437
Feasibilty of in utero DNA vaccination following naked gene transfer into pig fetal muscle: transgene expression, immunity and safety 433
Thymosin alpha 1: from bench to bedside 433
Combined treatment with thymosin-alpha 1 and low dose interferon-alpha after dacarbazine in advanced melanoma 425
Access to patient-level trial data--a boon to drug developers 424
TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death. 421
Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union 420
Detection of high levels of Survivin-immunoglobulin M immune complex in sera from hepatitis C virus infected patients with cirrhosis 417
Treatment of aspergillus infection with thymosin alpha 1 413
The risks of risk aversion in drug regulation 406
Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma 405
Transcription profile of human lymphocytes following in vitro treatment with thymosin alpha-1 403
Drug policy for an aging population--the European Medicines Agency's geriatric medicines strategy 403
Differential expression of a new tumor-associated antigen, TLP, during human colorectal cancer tumorigenesis 402
Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats 393
Combination low-dose lymphoblastoid interferon and thymosin α1 therapy in the treatment of chronic hepatitis B 391
Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling 387
Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies 387
Anti-tumour immunogens and vaccines 386
null 385
Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a 382
Combination therapy with BRMs in cancer and infectious diseases 381
null 380
High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma 377
The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation 377
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma 374
comparative cellular signal patway analysis of metastatic colorectal cancer in human and preclinical animal model 373
An audience with Guido Rasi. Interview by Asher Mullard 373
Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee 368
Evaluation of antigen specific recognition and cell mediated cytotoxicity by a modified lysispot assay in a rat colon carcinoma model 366
Combination thymosin alpha(1) and lymphoblastoid interferon treatment in chronic hepatitis C 364
Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional healthcare providers 359
Straight talk with...Guido Rasi. Interview by Roxanne Khamsi 359
ACTIVATION OF HUMAN ENDOGENOUS RETROVIRUS-K AND PRODUCTION OF INFECTIOUS VIRUS-LIKE PARTICLES IN HUMAN MELANOMA CELLS ABS -0153 358
nerve growth factor (ngf) and cirrhosis: a possible new marker of progression to hepatocellular carcinoma (hcc) 354
differentiation therapy: in vitro evidence making cyanidin-3-o--glucopiranoside useful for prevention and treatment of melanoma 352
Fifty years after thalidomide; what role for drug regulators? 352
Microfabricated biocapsules provide short-term immunoisolation of insulinoma xenografts 351
Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma 349
up-regulation of melanocytic differentiation antigens induced by cyanidin-3-o--glucopyranoside in human melanoma cells. 348
Stimulatory effect of Eucalyptus essential oil on innate cell-mediated immune response 347
Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application 347
COMPARATIVE CELLULAR SIGNAL PATWAY ANALYSIS OF METASTATIC COLORECTAL CANCER IN HUMAN AND PRECLINICAL ANIMAL MODEL 346
early detection of molecular markers suitable for colorectal cancer diagnosis and therapy in a carcinogenesis model 346
Method of up-regulating tumor antigen expression using thymalfasin 345
Preclinical studies using oncofidä-s, a new sn38-hyaluronic acid bioconyugate, for cd44-targeted therapy of colon carcinoma 343
null 342
Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. 341
Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha 1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery 334
Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo 331
Differentiation of human melanoma cells induced by cyanidin-3-O-beta-glucopyranoside 329
up-regulation of melan-a/mart-1 antigen expression during human melanoma cell differentiation 328
preventive peptide vaccine for colorectal cancer metastases 327
Survivin-Igm Immuno Complex: A Novel Candidate Biomarker Of Cirrhosis To Monitor Patients Progression Towards Hepatocellular Carcinoma 325
Cytoplasmic localization of anthracycline antitumor drugs conjugated with reduced glutathione: a possible correlation with multidrug resistance mechanisms 323
Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice 320
nerve growth factor (ngf): a possible marker for hepatocellular carcinoma (hcc)? 320
Characterization of four newly established melanoma cell lines 320
Influenza della concentrazione di adriamicina su modificazioni volumetriche e proliferazione di cellule leucemiche in vitro 311
Rationale for therapeutic approaches with thymic hormones, interleukin 2 and interferon in combination with chemotherapy. 293
Stimolazione in vivo mediante prostaglandine ed interferone dell'attività natural killer in topi trattati con ciclofosfamide. vol. 87, p. 595-603 291
WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer 285
Metformin induces apoptosis and downregulates pyruvate kinase M2 in breast cancer cells only when grown in nutrient-poor conditions 211
A new tumour associated antigen of non-small cell lung cancer: Tumour Liberated Proteins (TLP) - A possible new tumor marker 200
A new tumour associated antigen of non-small cell lung cancer: Tumour liberated proteins (TLP) - A possible new tumor marker 179
Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: A phase-II controlled trial 175
Open clinical trial data for all? A view from regulators 163
Sequential biochemotherapy for metastatic colorectal cancer using, fluorouracil, folinic acid, thymopentin and interleukin-2: Clinical and immunological effects 161
BIOCHEMOTHERAPY WITH THYMOSIN-ALPHA-1, INTERLEUKIN-2 AND DACARBAZINE IN PATIENTS WITH METASTATIC MELANOMA - CLINICAL AND IMMUNOLOGICAL EFFECTS 143
Clinical trial publications: A sufficient basis for healthcare decisions? 123
Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma 120
From adaptive licensing to adaptive pathways: Delivering a flexible life-span approach to bring new drugs to patients 105
Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation 104
Asthma, allergy and the olympics: A 12-year survey in elite athletes 101
Innovative medicines: New regulatory procedures for the third millennium 95
Transparency and the European medicines agency - Sharing of clinical trial data 92
How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice 89
Big Data – How to Realize the Promise 89
Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals? 89
Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward 88
European regulatory experience with drugs for central nervous system disorders 86
First-in-human clinical trials - What we can learn from tragic failures 85
The impact of parallel regulatory–health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations 82
preventive peptide vaccine for colorectal cancer metastases 79
Drug regulation and pricing - Can regulators influence affordability? 78
Steps forward in regulatory pathways for acute and chronic heart failure 75
Inhibitor of fatty acid amide hydrolase: learning from tragic failures [The editorialists reply] 67
Pharmacovigilance 2030: Invited Commentary for the January 2020 “Futures” Edition of Clinical Pharmacology and Therapeutics 59
High CD169 Monocyte/Lymphocyte Ratio Reflects the Immunophenotyping Disruption and Predicts Oxygen Need in COVID-19 Patients 55
High CD169 monocyte/lymphocyte ratio reflects immunophenotype disruption and oxygen need in COVID-19 patients 50
The COVID-19 crisis as an opportunity to strengthen global regulatory coordination for sustained enhanced access to diagnostics and therapeutics 43
Preliminary Evidence of the Differential Expression of Human Endogenous Retroviruses in Kawasaki Disease and SARS-CoV-2-Associated Multisystem Inflammatory Syndrome in Children 38
Development of a digital research assistant for the management of patients’ enrollment in oncology clinical trials within a research hospital 37
Totale 29.050
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.573
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.573
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.838 0 0 0 0 544 730 611 589 562 531 638 633
2020/20215.112 596 669 588 596 461 615 637 443 148 128 188 43
2021/2022985 32 115 45 26 24 92 78 38 94 67 58 316
2022/20231.166 128 53 45 120 91 294 98 79 81 12 141 24
2023/2024319 40 8 31 18 30 67 11 11 2 12 13 76
2024/20251.164 69 591 320 136 48 0 0 0 0 0 0 0
Totale 29.353